Mutations in particular nucleotides of genes coding for drug targets or drug-converting enzymes lead to drug resistance in Mycobacterium tuberculosis. For rapid detection of drug-resistant M. tuberculosis in clinical specimens, a simple and applicable method is needed. Eight TaqMan minor groove binder (MGB) probes, which discriminate one-base mismatches, were designed (dual-probe assay with four reaction tubes). The target of six MGB probes was the rpoB gene, which is involved in rifampin resistance; five probes were designed to detect for mutation sites within an 81-bp hot spot of the rpoB gene, and one probe was designed as a tuberculosis (TB) control outside the rpoB gene hot-spot. We also designed probes to examine codon 315 of katG and codon 306 of embB for mutations associated with resistance to isoniazid and ethambutol, respectively. Our system was M. tuberculosis complex specific, because neither nontuberculous mycobacteria nor bacteria other than mycobacteria reacted with the system. Detection limits in direct and preamplified analyses were 250 and 10 fg of genomic DNA, respectively. The system could detect mutations of the rpoB, katG, and embB genes in DNAs extracted from 45 laboratory strains and from sputum samples of 27 patients with pulmonary TB. This system was much faster (3 h from DNA preparation) than conventional drug susceptibility testing (3 weeks). Results from the dual-MGB-probe assay were consistent with DNA sequencing. Because the dual-probe assay system is simple, rapid, and accurate, it can be applied to detect drug-resistant M. tuberculosis in clinical laboratories.
Tuberculosis (TB) presents a significant health threat to the world's population, with 8 million new cases of disease and 2 million deaths per year (36). To minimize the emergence and spread of drug-resistant TB, the basic principle of anti-TB treatment is to administer multiple drugs to which the organism is susceptible. Strains of Mycobacterium tuberculosis that are resistant to anti-TB drugs are being encountered with increased frequency (7) . The major risk factors for drug resistance include inadequate prescription and delivery of chemotherapy, poor compliance, and an insufficient number of active drugs in the treatment regimen. The emergence of drug-resistant strains threatens our capability to control TB (2) . Multidrug-resistant (MDR) M. tuberculosis, defined as simultaneous resistance to at least isoniazid (INH) and rifampin (RIF), is a serious problem. Strains of MDR M. tuberculosis appear to result from the stepwise acquisition of mutations in the genes encoding drug targets or drug-converting enzymes (10) .
Rapid detection of susceptibility or resistance is crucial for TB treatment, because the initial choice of effective drugs is important. Major anti-TB drugs include INH, RIF, and ethambutol (EMB). Genetic studies have demonstrated that more than 95% of RIF resistance is associated with a mutation in the 81-bp core region of the rpoB gene (26, 31) . RIF-susceptible mycobacteria do not possess the known mutations in core region of the rpoB gene. Therefore, mutations in the rpoB gene indicate that bacteria are RIF resistant. By contrast, INHresistant strains exhibit mutations in several genes, such as katG, inhA, oxyR, and ahpC (22, 27, 30) . The mutation of codon 315 (Ser) in the catalase-peroxidase (katG) gene is the most frequent site (30 to 65% of resistant strains) (4, 11) . Furthermore, EMB-resistant strains have a point mutation at codon 306 (Met) in embB (3, 28) , and the frequency is about 70% (3) . Mutations of these sites are merely one mechanism leading to drug resistance. Many clinical isolates of drug-resistant M. tuberculosis do not bear mutations in these sites. Even if all of these mutations are examined, some resistant bacteria remain undetectable. However, the presence of mutations in the sites indicates that these bacilli are drug resistant (sensitivity, Ͻ100%; positive predictive value, 100%). In drug susceptibility testing, the culture method remains the "gold standard" (15) . Since culture requires at least 2 weeks to obtain results (20) , rapid diagnosis of drug resistance provides new opportunities for chemotherapeutic intervention in TB.
Because TaqMan minor groove binder (MGB) probes can distinguish one-base mismatches, the real-time PCR system in combination with MGB probes has been applied to analyze single-nucleotide polymorphisms (1, 12) . It has been proven that the specificity of MGB probes is quite high (18) . In the present study, we have developed a real-time PCR-based system with TaqMan MGB probes to detect the mutations asso-certain luminescence intensity by each probe (⌬Rn ϭ 0.2) reflected the amount of DNA in the sample. This cycle number was called the threshold cycle (Ct). Therefore, the presence of a mutation would result in an increase in Ct.
Nested PCR was performed when signals were undetected in real-time PCR. The PCR was carried out in a 25-l reaction volume. The reaction mixture contained 1ϫ PCR buffer, 1 U of GC-rich enzyme mix (Roche Diagnostics Corp., Indianapolis, Ind.), a 200 M concentration of each of the four deoxynucleoside triphosphates, a 1 M concentration of three kinds of primer sets (Table 1) , 1 M GC-rich solution, 1.5 mM MgCl 2 , and 10 l of template DNA. The primer pairs for the rpoB, katG, and embB genes amplified 534-, 464-, and 408-bp fragments, respectively. The PCR conditions were as follows: initial denaturation at 94°C for 5 min and then 40 cycles of 94°C for 30 s, 60°C for 30 s, and 72°C for 30 s. After the first PCR, the amplified product was diluted 100-fold with sterilized water. One microliter of this solution was used for the real-time PCR analysis as described above.
IPC for detecting PCR inhibitors. For analysis of sputum samples from TB patients, an internal process control (IPC) was performed to detect PCR inhibitors PCR simultaneously. As IPC primers, each rpoB primer was added to the 5Ј end of the corresponding lambda phage primer ( Table 1 ). The identical sequence of the lambda phage IPC-R probe, which was 5Ј labeled with FAM and quenched with 6-carboxytetramethylrhodamine (TAMRA) at the 3Ј end, was used for analysis as described previously (13) .
Electrophoresis. Amplification products were separated on 3% agarose gels with 1ϫ Tris-acetate-EDTA buffer for 45 min at 100 V.
RESULTS

Real-time PCR.
For rapid detection of mutations in the rpoB, katG, and embB genes involving M. tuberculosis resistance to RIF, INH, and EMB, respectively, three primer pairs and eight MGB probes were designed ( Fig. 1 and Table 1 ). Five probes (rpo510/514, rpo514/520, rpo520/524, rpo524/529, and rpo529/533) were used for detection of mutations in the hot spot of rpoB (81 bp between codons 507 and 533 [equivalent to Escherichia coli numbering system {31}]). One probe (TB control probe) was designed outside the hot spot in rpoB as a control for determining the amount of DNA and for identifying M. tuberculosis. Polymorphisms in the 81-bp region of rpoB could be analyzed by using three tubes. One probe each for embB (codon 306) and katG (codon 315) was labeled with FAM and VIC, respectively. These probes were mixed with their four corresponding primers in one tube. Four tubes (three tubes for control and RIF resistance and one tube for INH and EMB resistance) were employed in the assay. Luminescence of all eight probes was detectable by real-time PCR with genomic DNA extracted from M. tuberculosis H37Rv as the template (Fig. 2A ). When the DNA had mutations in rpoB at position 516 and in katG at position 315, the corresponding probes showed no luminescence signal (Fig. 2B) . Typical results are shown in Fig. 2C and D. These results indicate that the probes used in this study can identify mutations of the target genes. Similar results were obtained by using autoclaved supernatants of M. tuberculosis suspensions instead of purified DNAs (data not shown).
Specificity and sensitivity. No luminescence was found when M. avium DNA (up to 50 ng) was analyzed in this system (Fig.  2E) ) . Therefore, the specificity of this system for the M. tuberculosis complex was sufficiently high.
By using purified genomic DNA from M. tuberculosis H37Rv, the sensitivity of this system was determined. In direct real-time PCR with the rpoB primer set and TB control probe, 100 fg of genomic DNA could be detected. Therefore, the mutation was detectable efficiently in the presence of 250 fg (Ct ϭ 37) of TB genomic DNA. The detection limit of the real-time PCR was 10 fg of DNA when combined with nested PCR (data not shown).
Assessment of real-time PCR. We extracted and sequenced genomic DNAs from 45 laboratory strains of RIF-resistant M. tuberculosis. They were classified into 20 groups based on their genotypes by nucleotide sequencing of M. tuberculosis DNAs ( Table 2 ). The luminescence intensity of TaqMan MGB probes in the real-time PCR amplification system was expressed as Ct. The Ct was higher when mutations were present in the genes. Using 45 RIF-resistant strains, we measured the Ct derived from an internal TB control probe bound outside the hot spots of the rpoB gene and ⌬Ct, which expressed the difference between the control and each MGB probe (Table 2 ). It was found that the ⌬Cts of probes hybridizing with the region without mutations were low (from Ϫ2.44 to 1.61) and that the Real-time PCR PCR primer rpoB
Internal process control IPC primer rpoB/lambda
DNA sequencing PCR and sequence rpoB
a Each TaqMan MGB probe was labeled with either FAM or VIC at the 5Ј end and with both a nonfluorescent quencher and an MGB at the 3Ј end. The IPC probe was labeled with FAM at the 5Ј end and TAMRA at the 3Ј end. The sequences of IPC primers in boldface correspond to the lambda phage DNA sequences (13).
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on August 29, 2017 by guest http://jcm.asm.org/ ⌬Ct was higher (Ն7) when mutations existed in the target DNA that should hybridize with the MGB probe. These results suggest that a ⌬Ct of more than 7 was associated with a mutation in the nucleotide sequence. No strains that had mutations within the codons 510 to 514 of the rpoB gene were found. To check to the specificity of the rpo510/514 probe, the rpoB gene was cloned and mutations were constructed at codons 511 (CTG3CCG) and 513 (CAA3CTA). Real-time FIG. 1. Design of TaqMan MGB probes for detection of mutations in the rpoB, embB, and katG genes. MGB probes were labeled with two different dyes (FAM or VIC). The DNA sample and PCR primers for rpoB amplification were mixed with each set of probes in three different tubes: (i) TB control and rpo520/524, (ii) rpo510/514 and rpo514/520, and (iii) rpo524/529 and rpo529/533 (A). The emb306 and kat315 probes and embB and katG PCR primers were mixed and reacted in another tube (B). The sequences of primers and probes are listed in Table 1 . PCR analysis with each construct as the template showed that the luminescence that was derived from probe rpo510/514 disappeared completely (data not shown). Clinical application of real-time PCR. DNAs extracted from sputa of patients with pulmonary TB were examined to assess to possibility of rapid detection of drug-resistant M. tuberculosis in clinical specimens by real-time PCR. Twenty-five clinical samples were culture positive, and two samples were culture negative. Nine samples were smear positive, and 18 samples were negative (Table 3) . Real-time PCR was used to analyze sputum samples for detection of mutations. Sample C5 had a mutation at codon 315 in the katG gene, and sample C11 possessed mutations at codon 531 in the rpoB gene, codon 315 in the katG gene, and codon 306 in the embB gene. These findings were in agreement with the results obtained by DNA sequencing. The drug susceptibility phenotypes of clinical isolates assessed by conventional culture methods were consistent with the genotypes (Table 3) . Thus, our real-time PCR system can detect mutations even when clinical samples, such as sputa, are used.
A total of 16 of 27 sputum samples (59.3%) showed strong luminescence in real-time PCR. By contrast, 11 samples showed no luminescence even after 40 cycles of PCR amplification. This was probably due to low concentrations, because IPC was positive for all 11 samples. Consequently, we performed site-specific nested PCR when the amount of DNA was small. The rpoB, katG, and embB genes were amplified by PCR with their corresponding primer sets (Fig. 3) . By optimizing the PCR conditions with six primers, three fragments that contained the target sites at a similar concentration were amplified (Fig. 3, lane 4) . The targets (rpoB, katG, and embB) were amplified by nested PCR with one tube. The targets were then analyzed by using real-time PCR. Nested PCR products could be analyzed for the presence of mutations associated with drug resistance, although DNA was undetectable in a single-step real-time PCR in these 11 samples. When nested PCR was used before real-time PCR, analysis of all 27 samples could be performed appropriately (Table 4) . However, in analysis of clinical samples, the Ct was more variable, resulting in a larger ⌬Ct (from Ϫ3.40 to 3.15) than for purified DNAs extracted from laboratory strains (from Ϫ2.44 to 1.61).
DISCUSSION
The TaqMan MGB probes are currently used for detection of single-nucleotide polymorphisms, because they can distinguish one-base mismatches (1, 12, 18 ). In the present study, we have attempted to apply these probes to detect drug resistance on a genetic basis. The implication of all studies on the genetic basis of antimicrobial resistance in M. tuberculosis is that the MDR phenotype (defined as simultaneous resistance to at least INH and RIF) is the result of accumulative mutations (10, 23) . The major anti-TB drugs are INH, RIF, and EMB. Among them, INH and RIF are the most potent agents. More than 90% of RIF-resistant M. tuberculosis isolates possess a point mutation at the hot spot in the 81-bp region of rpoB (3, 26) . For that reason, detection of mutations in the rpoB gene is a quite useful strategy for diagnosis.
The present study also analyzed extracted DNAs from M. tuberculosis by real-time PCR for the presence of mutations in the katG (codon 315) and embB (codon 306) genes. Codons 315 in katG and 306 in embB were selected because mutations at these sites have been observed frequently in INH-and EMB-resistant M. tuberculosis (3, 4, 11, 28) . However, the role of codon 306 in the embB gene for EMB resistance remains controversial, because the mutation has also been found in EMB-susceptible M. tuberculosis. It has been reported that embB306 mutations were detected in 48% of EMB-resistant strains and in 31% of EMB-susceptible strains (21) . In particular, 60% of EMB-susceptible strains were resistant to rifampin and isoniazid (i.e., MDR), but none of pansusceptible strains harbored an embB306 mutation. A discrepancy between the results of phenotypic and genotypic analyses of EMB resistance tests was restricted to the strains that were already resistant to other anti-TB drugs, such as MDR M. tuberculosis. Our results have shown that 42% of EMB-susceptible strains of MDR M. tuberculosis had the mutation, in contrast to 0% of pansusceptible strains. When a mutation exists at embB306 in MDR M. tuberculosis, it is possible that the strain is susceptible to EMB. Nevertheless, 70% of EMB-resistant strains have a point mutation at codon 306 in the embB gene (3, 28) . The mutation of codon 315 (Ser) in the katG gene is the most frequently encountered mutation that is associated with INH resistance (30 to 65%) (4, 11) . In the present study, we found that 70% of INH-resistant strains and 6% of INH-susceptible strains had the mutation at this site. These results are consistent with previous reports (4, 11, 21) .
The results obtained from the real-time PCR system in this study were consistent with DNA sequencing analyses of 45 laboratory strains and 27 clinical samples. The system did not react with DNAs prepared from K. pneumoniae, P. aeruginosa, S. aureus, and nontuberculous mycobacteria but reacted solely with DNAs from isolates belonging to the M. tuberculosis com- FIG. 3 . DNA analysis of amplicons by simplex and multiplex PCRs. DNA from sputum sample C1 was amplified by using primers for the rpoB, embB, and katG genes. The product sizes of their amplicons were 534, 408, and 464 bp, respectively (lanes 1 to 3, respectively). Three kinds of primer sets for the rpoB, embB, and katG genes were mixed, and multiplex PCR was performed (lane 4). The M lane was a DNA molecular size marker which contained the 100-bp ladder.
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Although understanding the mechanisms of drug resistance has practical implications for rapid detection of drug-resistant TB by molecular methods, there are a number of limitations to widespread use of PCR-based techniques. For one, resistance to anti-TB agents involves changes in multiple genes and at multiple possible locations within a gene. This fact complicates testing for the various genes. In addition, not all possible genes or mechanisms of resistance have been identified, which represents a significant drawback for diagnostics.
It has been reported previously that real-time PCR with MGB probes was applied for detection of INH-resistant M. tuberculosis (34) . In that study, DNAs prepared from smearpositive sputa were used. However, the results for certain samples were inconsistent with those of DNA sequencing. One possible explanation for this is that the amount and/or quality of DNA was not standardized in the study (34) . Our results suggest that the amount of DNA in the sample is critical for analysis with real-time PCR using TaqMan MGB probes. The quality of DNA (e.g., whether it is inhibitor free) is also important. In the present study, two control probes were designed for the real-time PCR. One was a TB control probe for identification of M. tuberculosis and confirmation of DNA amount; the other was the IPC for detection of PCR inhibitors. If luminescence is not detected, the reason mentioned above can be suspected.
Several molecular methods to detect drug-resistant M. tuberculosis have been reported (8) . These methods are fundamentally based on the detection of point mutations. PCR-DNA sequencing is a straightforward technology to detect mutation (14) , although it takes 1 to 2 days until the result is obtained. Methods based on real-time PCR have utilized fluorescence resonance energy transfer (FRET) probes (9, 32), molecular beacons (6, 23, 24) , and TaqMan MGB probes (34) . By using the real-time PCR as described here, the time to obtain results for drug susceptibility or resistance can be shortened to as little as 3 h from the preparation of DNAs from isolates of M. tuberculosis and sputum samples. Rapid detection of drug resistance or susceptibility may open new therapeutic avenues for intervention in diseases in which drug resistance is a major impediment to treatment. The method based on FRET probes requires a longer probe, because it utilizes both sensor and anchor probes (33) . The shift of melting temperature was unclear in some cases when long probes were used in FRET analysis to detect mutations. By contrast, molecular beacons and TaqMan MGB probes, which can be designed to be shorter than FRET probe, detect the mutations on the basis of either emission or lack of emission of luminescence. The luminescence can be measured with a fluorescence plate reader after conventional PCR, even without a real-time PCR analyzer (5).
Molecular beacons are an alternative approach to detect drug-resistant organisms in a real-time format. It has been reported that RIF-resistant M. tuberculosis can be detected in a one-tube reaction by using the beacons (6) . This is a convenient and simple method to detect mutations. However, it is necessary to use a real-time PCR analyzer that can detect five kinds of different luminescence simultaneously. Although the assay described here requires the use of four tubes per sample, only two wavelengths are employed, enabling the use of less advanced equipment.
Our present study suggests that drug-resistant M. tuberculosis can be detected by ⌬Ct with TaqMan MGB probes in real-time PCR. Based on the result for 45 laboratory strains and 27 clinical samples of M. tuberculosis, ⌬Ct was less than 3.5 when organisms had no mutation (Tables 2 and 3 ). When ⌬Ct was more than 6, the DNA samples contained mutations within the target region. These isolates or samples are strongly inferred to be drug-resistant M. tuberculosis (Tables 2 and 3) . When wild-type and mutated DNAs were mixed at ratios ranging from 8:2 to 2:8, ⌬Ct was distributed between 3.5 and 6.0 (data not shown). Indeed, ⌬Ct of a mixture of drug-susceptible and -resistant bacilli ranged from 3.5 to 6.0. When ⌬Ct is distributed within the range of 3.5 to 6.0, DNA sequencing analysis should be performed to confirm the mixture. In analysis of clinical samples without mutations, the range of ⌬Ct became larger (Ϫ3.40 to 3.15) than that of purified DNAs extracted from laboratory strains (Ϫ2.44 to 1.61). It is thought that ⌬Ct obtained from the real-time PCR is a useful marker for discriminating between drug-susceptible and drug-resistant M. tuberculosis strains. These criteria are applicable to detect drug-resistant M. tuberculosis in clinical laboratories.
Real-time-based PCR shows sufficient specificity and sensitivity to detect drug-resistant M. tuberculosis even with sputum samples from TB patients without culture. The real-time PCR described here can detect drug-resistant M. tuberculosis within 3 h from DNA preparation. For those reasons, it may be a powerful tool for control of drug-resistant M. tuberculosis. a DNAs were extracted from sputa of TB patients by use of the AMPLICOR respiratory specimen preparation kit.
b DNAs from sputa were analyzed after preamplification by nested PCR.
